Zdrowie i gospodarka · 19/02/2019
FDA Announces Final Guidance for Expedited Development of Regenerative Medicine Therapies for Serious Conditions
The FDA has released a final guidance document outlining expedited development and review procedures for regenerative medicine therapies intended to treat serious or life-threatening diseases, providing industry sponsors with recommendations and interactions with the CBER review staff.